Prognosis of primary percutaneous coronary intervention in elderly patients with ST-elevation myocardial infarction

Abdullah Alkhushail\textsuperscript{a,b,⇑}, Sanjay Kohli\textsuperscript{b}, Andrew Mitchel\textsuperscript{b}, Robert Smith\textsuperscript{b}, Charles Ilsely\textsuperscript{b}

\textsuperscript{a}Department of Cardiology, Prince Sultan Cardiac Center, Riyadh
\textsuperscript{b}Department of Cardiology, Harefield Hospital, London
\textsuperscript{a} Saudi Arabia
\textsuperscript{b} United Kingdom

\textbf{Objective:} To evaluate the prognosis of primary percutaneous coronary intervention (PPCI) and medical therapy (MT) in elderly patients presenting with ST-elevation myocardial infarction (STEMI).

\textbf{Methods:} A total of 238 STEMI patients aged above 80 and treated with PPCI \((n = 186)\) and MT \((n = 52)\) at Harefield Hospital, London were included in this study. Patients who did not have true STEMI based on non-diagnostic electrocardiogram (ECG) for STEMI and negative troponin, who presented with left bundle branch block (LBBB) and had normal coronaries were excluded from this study. Primary PCI was defined as any use of a guidewire for more than diagnostic purposes in patients with STEMI, whereas conventional MT was defined as treatment of patients with anti-platelets and anti-thrombotic medications without thrombolysis.

\textbf{Results:} The survival rate of PPCI patients was 86\% \((n = 160)\) at month 1 followed by 83.9\% \((n = 156)\) at month 6, and 81.2\% \((n = 151)\) at month 12. The survival rate of MT patients was 44.2\% \((n = 23)\) at month 1 followed by 36.5\% \((n = 19)\) at month 6, and 34.6\% \((n = 18)\) at month 12. Compared to MT, significantly fewer comorbidities were found in the PPCI group. Ventricular fibrillation (VF) (4.8\%) and consequent admission to intensive care unit (7\%) were the major complications of the PPCI group.

\textbf{Conclusion:} PPCI has a higher survival rate and, compared to MT, fewer comorbidities were observed in the PPCI group of elderly patients presenting with STEMI.

\copyright\ 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

\textbf{Keywords:} Myocardial infarction, Coronary intervention, Survival rate

\section*{Introduction}

Cardiovascular disease (CVD) is the leading cause of death worldwide, and coronary artery disease (CAD) is the most prevalent manifestation associated with high mortality and morbidity [1]. Heart failure is the end-stage of several cardiovascular diseases such as acute myocardial infarction (AMI), and it remains a major challenge for regenerative medicine because of...
its high prevalence and incidence in elderly patients [2]. However, the long-term incidence of heart failure (HF) in patients with ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina (UA) is uncertain [3].

Studies report cardiovascular disease as the leading cause of death in the elderly and describe its direct correlation with aging [4]. The elderly may experience higher mortality from STEMI due to severe comorbidities, advanced CAD, as well as mechanical and electrical complications of AMI [5,6]. Further, several disorders often coexist in the elderly such as ischemic heart disease (IHD), hypertension, diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), chronic renal failure, digestive system disorders as well as joint and bone disorders, which occur more often in this group of patients [6–10]. Cardiologists are therefore increasingly confronted with the management challenges of elderly patients presenting with STEMI. Optional management of acute coronary syndromes in this population has been an area of uncertainty as there is a paucity of evidence-based data due to their exclusion and under-representation in clinical trials [11].

Primary percutaneous coronary intervention (PPCI) and pharmacologic therapy are widely used and constitute a vital treatment strategy for AMI [12–14]. PPCI therapy must be initiated prior to angiography (pretreatment), and continued during the procedure (periprocedural), recovery phase (in-hospital), and follow-up [15]. The purpose of this study is to evaluate the prognosis of PPCI and medical therapy (MT) in elderly patients presenting with STEMI.

Table 1. The demographic, BMI and hospital length of stay of the study population.

| Variables                     | Angioplasty | Medical |
|-------------------------------|-------------|---------|
| **Gender**                    |             |         |
| Male                          | 80 (43%)    | 27 (52%)|
| Female                        | 106 (57%)   | 25 (48%)|
| Total                         | 186         | 52      |
| **Age**                       |             |         |
| 80–85                         | 128 (68.8%) | 32      |
| ≥86–90                        | 42 (22.5%)  | 14      |
| ≥91–95                        | 14 (7.52%)  | 6       |
| ≥96                           | 2 (1.07%)   | 0       |
| **BMI**                       |             |         |
| Male                          | 24.4        | 24.3    |
| Female                        | 24.9        | 25.1    |
| **Hospital length of stay**   |             |         |
| HLOS                          | 3 (2–5 days)| 4 (2–7 days) |

Abbreviations
PPCI primary percutaneous coronary intervention
PCI percutaneous coronary intervention
MT medical therapy
STEMI ST-elevation myocardial infarction
ECG electrocardiogram
LBBB left bundle branch block
VF ventricular fibrillation
ICU intensive care unit
CVDs cardiovascular diseases
CAD coronary artery disease
AMI acute myocardial infarction
HF Heart Failure
NSTEMI non-ST-elevation myocardial infarction
UA unstable angina
IHD ischemic heart disease
DM diabetes mellitus
COPD chronic obstructive pulmonary disease
HLOs hospital length of stay
BMI body mass index
GUSTO-1 Global Utilization of Streptokinase and Tissue Plasminogen Activator to treat Occluded Arteries
t-PA tissue plasminogen activator
PAMI-1 Primary Angioplasty in Myocardial Infarction

Methods
We conducted a retrospective study on 301 STEMI patients (aged ≥80) treated with PPCI and MT at Harefield Hospital, London during the period between January 2005 and February 2010. Sixty-three patients were excluded from the study as they did not have true STEMI based on non-diagnostic ECG for STEMI and negative troponin, or had presented with left bundle branch block (LBBB) and had normal coronaries.

ST-elevation myocardial infarction was defined as the presence of ST-elevation or new left bundle branch block on electrocardiography in addition to suspicion of ongoing ischemia. Primary PCI was defined as any use of a guidewire for more than diagnostic purposes in patients with STEMI. Conventional MT was defined as treatment with anti-platelets and anti-thrombotic medications without thrombolysis. The demographic variables, body mass index (BMI), comorbidities and hospital length of stay (HLoS) were also collected for analysis. The protocol of the study was approved by the research ethics committee of the hospital.

Data analysis was carried out using Microsoft Excel 2002 (Microsoft Corporation, Seattle, WA, USA), and the Statistical Package for Social Sciences version 16 (SPSS Inc., Chicago, IL, USA). Data were presented as percentage and mean ± standard error of mean. Chi-square test was used to compare the differences between comorbidities of PPCI and MT, while Mann–Whitney U test was used to compare the HLoS. P-value of <0.05 was considered statistically significant.
Results

Demographics, BMI, and hospital length of stay of the study population are shown in Table 1. A total of 186 patients were treated with PPCI and 52 patients were treated with conventional MT. There were 107 (45%) males and 131 females (54%). The mean age of the PPCI group was 83.92 years and 84.76 years for the MT group (P > 0.05). The MT group HLoS (four days) was higher than the PPCI group (three days), (P = 0.039). The survival of the PPCI group is demonstrated in Fig. 1. The survival rate of PPCI patients showed 86% (n = 160) at month 1 followed by 83.9% (n = 156) at month 6, and 81.2% (n = 151) at month 12. The survival rate of the MT group is demonstrated in Fig. 2. The survival rate of MT patients showed 44.2% (n = 23) at month 1 followed by 36.5% (n = 19) at month 6, and 34.6% (n = 18) at month 12. The Kaplan–Meier survival curves of PPCI are shown in Fig. 3. The comorbidities of the PPCI and medical groups during

![Figure 1. Survival rate (% n) of primary percutaneous coronary intervention (n = 186).](image1)

![Figure 2. Survival rate (% n) of medical therapy (n = 52).](image2)

![Figure 3. Survival curve: primary percutaneous coronary intervention patients.](image3)
admission are shown in Fig. 4. Compared to stroke, Renal Failure (RF) and cancer, hypertension and DM were the major comorbidities in both groups. Compared to MT, significantly fewer comorbidities were found in the PPCI group. Complications related to PPCI during admission are shown in Fig. 5. Ventricular fibrillation (VF) (4.8%) and consequent admission to intensive care unit (7%) were the major complications of PPCI.

Discussion

The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial demonstrated that the 30-day mortality rate for STEMI increased tenfold among the elderly, from 3.0% in the age group of <65 years to 30.3% among those >85 years of age [16]. This high mortality rate in the very elderly was also confirmed by several other studies [17–21]. On the other hand, several large multi-center trials have demonstrated that reperfusion therapy of STEMI, whether primary percutaneous coronary intervention (PCI) or fibrinolysis, improved mortality for elderly patients [5]. In the present study, we also observed that treatment with PPCI was feasible and beneficial for patients with STEMI.

Limited research has been conducted on the prognosis of PPCI management of STEMI in the elderly. There are few trials comparing PPCI with fibrinolytic therapy, which enroll an adequate number of older patients. Existing subset analyses from trials, which randomized patients to primary PCI or fibrinolytic therapy, suggest that PCI is a preferred strategy in older patients. The PPCI in the Primary Angioplasty in Acute Myocardial Infarction (PAMI-1) study randomized patients to immediate PCI or fibrinolytic therapy, and observed that the greatest benefit was in patients over 65 years. There was no significant reduction in the combined endpoint of death/MI in patients under 65 years (0.8% mortality in both groups), but there was a marked reduction in the same endpoint in patients >65 (death/MI was 8.6% with angioplasty versus 20% with tPA) [22]. In the GUSTO-IIB trial, the largest randomized trial comparing angioplasty with thrombolytic therapy, 1138 patients were randomized to receive either accelerated tPA or primary angioplasty. Although
primary angioplasty resulted in better 30-day outcomes (death/MI (myocardial infarction) 1 stroke occurred in 9.6% versus 13.7% with tPA), there was no significant difference in death/MI at six months (13.3% versus 15%, respectively) [23]. The recent Tratamiento del Infarto Agudo de miocardio en Ancianos (TRIANA) trial showed a trend towards improved outcomes for patients treated with PCI versus fibrinolysis with a combined end point of death, recurrent MI and disabling stroke at 30 days. PCI patients had marked improvement of recurrent ischemia. In the previous SENIOR-PAMI trial, similar results were obtained, but a subgroup analysis of patients >80 years of age showed no benefit of PCI over fibrinolysis [24]. The present study shows that the survival rate of PPCI patients was 86% (n = 160) at month 1, followed by 83.9% (n = 156) at month 6, and 81.2% (n = 151) at month 12. It also suggests that patients treated with PPCI for STEMI have good prognosis if they survive the initial months. A recent study reported that PCI is the preferred treatment for patients with STEMI owing to improved vessel patency, decreased infarct size, lower rates of reinfarction, and improved survival compared to pharmacological reperfusion [25].

There is little in the literature to direct and guide STEMI therapy in elderly patients, especially those whose age is greater than or equal to 80 years [5]. Elderly patients usually have complex CAD with higher mortality and morbidity, and higher rates of complication following PPCI, such as stroke and renal failure [5,26–28]. Advanced age is an independent predictor of mortality after PPCI, and elderly patients show a larger prevalence of female gender, hypertension, and diabetes [17], which was confirmed in our study. We observed that hypertension and DM were the major co-morbidities of both the PPCI and MT groups. Overall, the patients treated with PPCI had fewer comorbidities compared to the patients treated with MT, which means that our hospital had selected the right patients for PPCI to ensure a better outcome. We also found a benefit in HLoS, which was shorter in the PPCI group. The MT group HLoS (four days) was higher than the PPCI group (three days).

Major limitations of this study were the relatively small number of patients, the limited number of risk factors examined, the study’s retrospective nature, and that samples were from a single hospital. However, despite its retrospective nature, the present study is important in light of the paucity of evidence-based clinical outcome data due to research exclusion and under-representation.

in the elderly STEMI patient group. In future, absolute and relative risks for efficacy and safety in age subgroups should be reported and trials should make an effort to enroll the elderly in proportion to their prevalence among the treated population. Outcomes of particular relevance to the older adult, such as quality of life, physical function, and independence should also be evaluated and geriatric conditions unique to this age group, such as frailty and cognitive impairment, should be considered for their influence on care and outcomes. With these efforts, treatment risks can be minimized and benefits can be placed within the health context of elderly patients.

References

[1] Tsounis D, Defteros S, Bouras G, Giannopoulos G, Anastoliotakis N, Raisakis K, et al. High sensitivity troponin in cardiovascular disease. Is there more than a marker of myocardial death? Curr Top Med Chem 2013;13(2):201–15.
[2] Gálvez-Montón C, Prat-Vidal C, Roura S, Soler-Botija C, Bayes-Genis A. Update: innovation in cardiology (IV). Cardiac tissue engineering and the bioartificial heart. Rev Esp Cardiol (Eng Ed) 2013;66(5):391–9.
[3] Kaul P, Ezekowitz JA, Armstrong PW, Leung BK, Savu A, Welsh RC, et al. Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J 2013;165(3):379–85. e2.
[4] Renilla A, Barreiro M, Barriales V, Torres F, Alvarez P, Lambert JL. Management and risk factors for mortality in very elderly patients with acute myocardial infarction. Geriatr Gerontol Int 2013;13(1):146–51.
[5] Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115(19):2570–89.
[6] Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, et al. Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndrome and stable angina. Int J Cardiol 2011;151(2):164–9.
[7] Covino M, Simeoni B, Montalto M, Burzotta F, Bucellletti F, Carbone L, et al. Reduced performance of Troponin T for acute coronary syndromes diagnosis in the elderly and very elderly patients: a retrospective study of 2688 patients. Eur Rev Med Pharmacol Sci 2012;16(Suppl. 1):8–15.
[8] Kizer JR, Benkeser D, Arnold AM, Djoussé L, Zieman SJ, Mukamal KJ, et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab 2013;98(1):255–63.
[9] Leveille SG. Musculoskeletal aging. Curr Opin Rheumatol 2004;16(2):114–8.
[10] Thomas LA. Effective dyspnea management strategies identified by elders with end-stage chronic obstructive pulmonary disease. Appl Nurs Res 2009;22(2):79–85.
[11] Parikh R, Chennareddy S, Debari V, Hamdan A, Konlian D, Shamoan F, et al. Percutaneous coronary interventions
in nonagenarians: in-hospital mortality and outcome at one year follow-up. Clin Cardiol 2009;32(12):E16–21.

[12] Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27(13):1530–8.

[13] Velders MA, James SK, Libungan B, Sarno G, Fröbert O, Carlsson J, et al. Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001–2011: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry. Am Heart J 2014;167(5):666–73.

[14] Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 2010;56(4):254–63.

[15] Kala P, Miklik R. Pharmaco-mechanic antithrombotic strategies to reperfusion of the infarct-related artery in patients with ST-elevation acute myocardial infarctions. J Cardiovasc Transl Res 2013;6(3):378–87.

[16] White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996;94(8):1826–33.

[17] De Luca G, van’t Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, et al. Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors. Heart Vessels 2014;29(1):15–20.

[18] Hovanesyan A, Rich MW. Outcomes of acute myocardial infarction in nonagenarians. Am J Cardiol 2008;101(10):1379–83.

[19] Kyriakides ZS, Kourouklis S, Kontaras K. Acute coronary syndromes in the elderly. Drugs Aging 2007;24(11):901–12.

[20] Ma C, Cao J, Lu XC, Guo XH, Gao Y, Liu XF, et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. J Geriatr Cardiol 2012;9(3):292–7.

[21] Mehta RH, O’Neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, et al. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol 2006;97(6):817–22.

[22] Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O’Keefe J, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995;25(2):370–7.

[23] A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997;336(23):1621–8.

[24] Grines C. Senior PAMI: a prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. J Am Coll Cardiol. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) annual conference; 2005 Oct 16–21; Washington, DC. 2005; 1–214.

[25] Räber L, Windecker S. Primary percutaneous coronary intervention and risk of stent thrombosis: a look beyond the HORIZON. Circulation 2011;123(16):1709–12.

[26] Kunimura A, Amano T, Uetani T, Harada K, Yoshida T, Suzuki A, et al. Prognostic impact of concurrence of metabolic syndrome and chronic kidney disease in patients undergoing coronary intervention: involvement of coronary plaque composition. J Cardiol 2013;61(3):189–95.

[27] Park KL, Budaj A, Goldberg RJ, Anderson Jr FA, Agnelli G, Kennelly BM, et al. Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]). Am J Cardiol 2012;110(5):628–35.

[28] Singh M, Holmes Jr DR, Gersh BJ, Frye RL, Lennon RJ, Rihal CS. Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients. Mayo Clin Proc 2013;88(1):22–30.